7th Edition of Cardiology World Conference
October 08-10, 2026 | Tokyo, Japan
Nanotechnology and Cardiovascular Medicine
Incorporating nanotechnology into the field of cardiovascular medicine is paving the way for new treatments that were once unimaginable. Nanotechnology and cardiovascular medicine are being combined to develop more precise drug delivery systems, allowing medication to be delivered directly to the heart, reducing systemic side effects and improving therapeutic outcomes. This breakthrough is also enhancing diagnostic tools, enabling earlier detection of cardiovascular diseases. The potential for nanomaterials to repair or regenerate damaged tissues and blood vessels provides a hopeful outlook for patients suffering from severe cardiovascular diseases. As this field continues to evolve, the integration of nanotechnology promises to redefine the future of heart disease management.
Yochai Birnbaum
Baylor College of Medicine, United States
Robert J Chilton
University of Texas Health Science Center San Antonio, United States
Yong Xiao Wang
Albany Medical Center, United States
Yochai Birnbaum
Baylor College of Medicine, United States
Robert J Chilton
University of Texas Health Science Center San Antonio, United States
Yong Xiao Wang
Albany Medical Center, United States
Narendra Kumar
HeartbeatsZ Academy, United KingdomSubmit your abstract Today
Title : New mechanisms and innovative therapeutics for pulmonary hypertension
Yong Xiao Wang, Albany Medical Center, United States
Title : STEMI versus acute occlusive myocardial infarction: Which term should we use?
Yochai Birnbaum, Baylor College of Medicine, United States
Title : Beyond weight loss and diabetes control GLP 1 agonists paradigm shift in Cardiovascular care .
Syed Raza, Awali Hospital, Bahrain
Title : CARDIAC TROPONIN AND HOMOCYSTEINE LEVELS IN HEMODIALYSIS PATIENTS: ASSOCIATION WITH DIALYSIS VINTAGE AND CARDIOVASCULAR COMORBIDITY
Sofra Maria, Aretaieion University Hospital, Greece
Title : Finite-Element and Electromagnetic Cardio-Vascular Simulation for Drug Testing, Monitoring, and Safety Projection Using Bansal B–Bio Framework
Abhishek Bansal, New Era Consultancy Services, India
Title : Lipid and High-Density Lipoprotein (HDL) Subfraction Changes in Premenopausal and Postmenopausal Women with Breast Cancer Receiving Hormonal Therapy
Sofra Maria, Aretaieion University Hospital, Greece